FindMyRecallSubscribe
Class II: temporary or reversible health riskOngoing

Glenmark Pharmaceuticals Ryaltris Recall

Ryaltris (olopatadine hydrochloride and mometasone fluorate) Nasal Spray, 665 mcg/25 mc…

Glenmark Pharmaceuticals Inc., USA · Mahwah, NJ

Risk level
Class II
Reported by FDA
Oct 9, 2024
Recall ID
D-0006-2025
Check your lot numberHow we source this data

Summary

Glenmark Pharmaceuticals recalled Ryaltris starting Sep 24, 2024. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-0006-2025 on Oct 9, 2024. Reason: Defective Delivery System: The dip tube is clogged causing the spray not to work. Status: Ongoing.

Why it was recalled

Defective Delivery System: The dip tube is clogged causing the spray not to work.

Product description

Ryaltris (olopatadine hydrochloride and mometasone fluorate) Nasal Spray, 665 mcg/25 mcg per spray, 240 Metered Sprays/bottle, 29 g net fill weight, Distr. by Hikma Specialty USA Inc., Columbus, OH 43328, hikma, Glenmark Specialty SA. NDC 59467-700-27.

Lot numbers, UPCs & expiration codes

Lots 14230425, Exp Date, Nov-25; 14240024, Exp Date Dec-25; 14240029, Exp Date Dec-25; 14240076, Exp Date Jan-26; 14240082 Exp Date, Jan-26, 14240090, Exp Date Jan-26; and 14240100, Exp Date Jan-26

Where it was sold

Nationwide in the USA

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-0006-2025
Classification
Class II
Status
Ongoing
Recall initiated
Sep 24, 2024
FDA report date
Oct 9, 2024
Quantity
45,504 bottles
Recall type
Voluntary: Firm initiated
Recalling firm
Glenmark Pharmaceuticals Inc., USA

Original FDA data

Every field from FDA enforcement report D-0006-2025, exactly as published.

Show all FDA fields
City
Mahwah
State
NJ
Status
Ongoing
Country
United States
Event ID
95389
Address
750 Corporate Dr
Code information
Lots 14230425, Exp Date, Nov-25; 14240024, Exp Date Dec-25; 14240029, Exp Date Dec-25; 14240076, Exp Date Jan-26; 14240082 Exp Date, Jan-26, 14240090, Exp Date Jan-26; and 14240100, Exp Date Jan-26
Postal code
07430-2009
Report date
Oct 9, 2024
Product type
Drugs
Recall number
D-0006-2025
Classification
Class II
Recalling firm
Glenmark Pharmaceuticals Inc., USA
Product quantity
45,504 bottles
Reason for recall
Defective Delivery System: The dip tube is clogged causing the spray not to work.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Ryaltris (olopatadine hydrochloride and mometasone fluorate) Nasal Spray, 665 mcg/25 mcg per spray, 240 Metered Sprays/bottle, 29 g net fill weight, Distr. by Hikma Specialty USA Inc., Columbus, OH 43328, hikma, Glenmark Specialty SA. NDC 59467-700-27.
Distribution pattern
Nationwide in the USA
Recall initiation date
Sep 24, 2024
Initial firm notification
Letter
Center classification date
Oct 3, 2024

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-0006-2025, published Oct 9, 2024. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls